EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma

Sonexai Kidoikhammouan, Charupong Saengboonmee, Sopit Wongkham, Wunchana Seubwai

Oncology Research · 2025 · 33 (12) · 3679-3699

DOI: 10.32604/or.2025.069027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Sonexai Kidoikhammouan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, 40002, Thailand. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Deoxycytidine, Drug Resistance, Neoplasm, Bile Duct Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma (CCA) is an aggressive cancer originating from bile duct epithelium. Surgical resection remains the primary curative treatment for CCA. However, most CCA patients are diagnosed at an advanced stage, which limits the applicability of surgical resection. Gemcitabine is widely used as a first-line chemotherapeutic agent for unresectable CCA. Its efficacy is often compromised by the development of drug resistance, which leads to poor clinical outcomes and low survival rates of CCA patients. At present, the mechanisms underlying gemcitabine resistance in CCA remain unclear. This review aimed to comprehensively summarize the current knowledge on the molecular mechanisms underlying gemcitabine resistance in CCA and highlight emerging therapeutic strategies that may overcome this resistance. Gemcitabine resistance arises through multiple mechanisms, including reduced drug uptake and increased efflux, impaired drug activation, enhanced DNA repair, apoptosis evasion, aberrations in cell-cycle progression, induction of epithelial-mesenchymal transition, metabolic reprogramming, alteration of tumor, and activation of oncogenic pathways contributes to gemcitabine resistance. A deeper understanding of gemcitabine resistance mechanisms highlights the need for combining gemcitabine with pathway-specific inhibitors, which hold promise for overcoming resistance and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaDeoxycytidineDrug Resistance, NeoplasmBile Duct NeoplasmsAntimetabolites, AntineoplasticHumansGemcitabineEpithelial-Mesenchymal TransitionApoptosisAnimals

Stichwörter der Autor:innen

Cholangiocarcinomabile duct cancerchemotherapydrug resistancegemcitabinemolecular mechanisms

Substanzen

GemcitabineDeoxycytidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, 40002, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
  • Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
  • Department of Forensic Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.

Zitieren

APA

Kidoikhammouan, S., Saengboonmee, C., Wongkham, S., & Seubwai, W. (2025). Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma. Oncology Research, 33(12), 3679-3699. https://doi.org/10.32604/or.2025.069027

Vancouver

Kidoikhammouan S, Saengboonmee C, Wongkham S, Seubwai W. Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma. Oncology Research. 2025;33(12):3679-3699. doi:10.32604/or.2025.069027

BibTeX
@article{Kidoikhammouan2025,
  author = {Kidoikhammouan, Sonexai and Saengboonmee, Charupong and Wongkham, Sopit and Seubwai, Wunchana},
  title = {Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma},
  journal = {Oncology Research},
  year = {2025},
  volume = {33},
  number = {12},
  pages = {3679--3699},
  doi = {10.32604/or.2025.069027}
}
Kostenlos starten →